Skip to main content

The Globe and Mail

Spectrum Pharma Inc (SPPI-Q) Quote

Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Price Quote as of

Today's Trading

Day Low 18.96
Day High 19.93
Price movement based on the high, low and last over the given period.
Previous Close
Average Volume
Price/Earnings (TTM)
Trailing Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Spectrum Pharmaceuticals, Inc. is opportunistically acquiring and advancing a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum's expertise lies in identifying undervalued drugs with demonstrated safety and efficacy, and adding value through further clinical development and selection of the most viable and low-risk methods of commercialization. The company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease.


Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share ttm
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings ttm
Trailing Annual Dividend & Yield
Ex-Div Date
Forward P/E
Most Recent Split


Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Biotech's Sprinting Into the New Year
PR Newswire - Wed Dec 27, 9:30AM CST
PR Newswire - CMTX
Wed Dec 27, 9:30AM CST
As we near the end of 2017, biotech companies are preparing for the first quarter of the New Year. As time progresses we continue to witness technology change lives in every possible way, biotechnology is one of the leading fields of technology and is changing modern medicine. Advancements in medicine happen at an increasing rate and technology creates new treatments that are developed faster than ever. This allows new therapies and drugs to be tested more quickly with results shared faster than ever before. Electroceutical therapy is one area within biotechnology that many experts consider to be a critical component of the future of medicine.
Spectrum Pharmaceuticals Announces Leadership Changes
BusinessWire - Sun Dec 17, 5:59PM CST
BusinessWire - CMTX
Sun Dec 17, 5:59PM CST
--Thomas J. Riga Named Chief Operating Officer
Pre-Market Technical Scan on Biotech Equities -- Spectrum Pharma, Jazz Pharma, Intra-Cellular Therapies, and Dermira
PR Newswire - Wed Dec 13, 6:05AM CST
PR Newswire - CMTX
Wed Dec 13, 6:05AM CST
In keeping with the commitment to dynamically provide members with timely information, has issued free tailored Stock Review on SPPI, JAZZ, ITCI, and DERM which is a click away at . On Tuesday, December 12, 2017, US markets saw four out of nine sectors finishing the day in red, three in green, and two in neutral territory. Major US indices were also mixed at the close of yesterday's session. The NASDAQ Composite ended the day at 6,862.32, down 0.19%; the Dow Jones Industrial Average edged 0.49% higher, to finish at 24,504.80; and the S&P 500 closed at 2,664.11, up 0.15%. This Wednesday morning, looks at the performance of these four Biotechnology stocks: Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), Intra-Cellular Therapies Inc. (NASDAQ: ITCI), and Dermira Inc. (NASDAQ: DERM). Get your free stock reports on these stocks by registering now on Wall St. Equities at:
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 15.93 +19.27% increase
on 12/20/17
Period Open:19.04
Price movement based on the high, low and last over the given period.
20.70 -8.21% decrease
on 12/18/17
-0.04 (-0.21%) decrease
since 12/15/17
3-Month 13.99 +35.81% increase
on 10/17/17
Period Open:13.94
Price movement based on the high, low and last over the given period.
21.95 -13.44% decrease
on 10/18/17
+5.06 (+36.30%) increase
since 10/16/17
52-Week 4.31 +340.84% increase
on 01/31/17
Period Open:4.65
Price movement based on the high, low and last over the given period.
21.95 -13.44% decrease
on 10/18/17
+14.35 (+308.60%) increase
since 01/13/17

All market data is provided by Barchart Solutions (will open in new tab). Copyright © 2018.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

More stories below advertisement